ProHeart

Therapy companion for patients with heart failure

The challenge

Heart failure (HF) is a severe clinical condition associated with high healthcare expenditure and mortality. In Germany, hospital admissions due to HF have risen steadily, resulting in 2.5 million patients in 2018.[1] This prevalence has been similarly observed in the wider European population, with a steady increase of 17% per year.[2]

Annual mortal risk for these patients is between 10% to 20%, higher than many cancers.[3]  HF patients, particularly those with multiple comorbidities, currently do not receive optimal medical therapy, leading to potentially avoidable specialist visits and frequent hospitalisations, impaired quality of life or even life-threatening complications. This constitutes a major public health burden.[4]

The solution

ProHeart is a therapy companion for patients with heart failure which empower healthcare professionals (HCPs) to implement best in class, hybrid care concepts. The solutions are patient-centred and supported by AI tools.

ProHeart’s solutions are CE marked and already reimbursed in Germany. Based on its own data, in Germany alone, the start-up estimates that its solutions have reached 2.5 million heart failure patients to date. The start-up now aims to access the French DiGA market (reimbursement system) with their strategic partners, Sanofi and Digital Pharma Lab, by the end of 2022.

To access the French reimbursement system, ProHeart will align their upcoming clinical study with the criteria needed to advance the process. They will consolidate findings with updates to their solutions. This includes monitoring the transition to common law for the coverage of remote monitoring, ensuring compliance with French requirements.

Expected impact

ProHeart’s solutions are expected to improve survival rates, health, quality of life, and overall patient safety, for heart failure patients. They also have the potential to improve the structure, processes, and guidance compliance around heart failure treatment. The start-up plans to evidence these claims through a clinical and economic study, in cooperation with their clinical partners.

References

[1] Holstiege, J, et. al. (2018). Prevalence of heart failure in Germany – nationwide trends, regional variation, and frequent comorbidities. Central Research Institute for Ambulatory Health Care in Germany. Versorgungsatlas-Report No. 18/09. DOI: 10.20364/VA-18.09.

[2] Holstiege, J, et. al. (2018).

[3] BigMedilytics (2021). Heart failure: Population health & chronic disease management. Available at: https://www.bigmedilytics.eu/pilot/heart-failure/.

[4] BigMedilytics (2021).